Mabwell (Shanghai) Bioscience Co (SHSE:688062) Piotroski F-Score: 5 (As of Jul. 03, 2026) — 25% Above Median


SHSE:688062 Mabwell (Shanghai) Bioscience Co Ltd SHSE:688062
61 GF Score
Price ¥32.06
GF Value ¥127.93
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Mabwell (Shanghai) Bioscience Co Piotroski F-Score?

Mabwell (Shanghai) Bioscience Co SHSE:688062 +4.84% 61 Piotroski F-Score is 5 as of Jul. 03, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates SHSE:688062 with a GF Score™ of 61/100 and a GF Value™ of ¥127.93 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,336 Biotechnology companies, Mabwell (Shanghai) Bioscience Co ranks better than 84.96% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Mabwell (Shanghai) Bioscience Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Mabwell (Shanghai) Bioscience Co's Piotroski F-Score or its related term are showing as below:

SHSE:688062' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 5

During the past 9 years, the highest Piotroski F-Score of Mabwell (Shanghai) Bioscience Co was 5. The lowest was 2. And the median was 4.

Mabwell (Shanghai) Bioscience Co  (SHSE:688062) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Mabwell (Shanghai) Bioscience Co Piotroski F-Score Related Terms


Mabwell (Shanghai) Bioscience Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Mabwell (Shanghai) Bioscience Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabwell (Shanghai) Bioscience Co Piotroski F-Score Chart

Mabwell (Shanghai) Bioscience Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 4.00 5.00 3.00 2.00 5.00

Mabwell (Shanghai) Bioscience Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 4.00 5.00 5.00

SHSE:688062 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Mabwell (Shanghai) Bioscience Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabwell (Shanghai) Bioscience Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabwell (Shanghai) Bioscience Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Mabwell (Shanghai) Bioscience Co's Piotroski F-Score falls into.


SHSE:688062
61GF Score
Mabwell (Shanghai) Bioscience Co Ltd SHSE:688062
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -259.591 + -46.341 + -371.674 + -241.944 = ¥-919.6 Mil.
Cash Flow from Operations was 182.692 + -69.107 + -187.192 + -234.163 = ¥-307.8 Mil.
Revenue was 56.377 + 464.673 + 96.677 + 127.597 = ¥745.3 Mil.
Gross Profit was 44.805 + 447.448 + 70.987 + 97.164 = ¥660.4 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(4191.356 + 4468.559 + 4527.089 + 4555.842 + 4568.347) / 5 = ¥4462.2386 Mil.
Total Assets at the begining of this year (Mar25) was ¥4,191.4 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,534.1 Mil.
Total Current Assets was ¥2,112.7 Mil.
Total Current Liabilities was ¥2,411.8 Mil.
Net Income was -239.324 + -249.108 + -349.829 + -291.728 = ¥-1,130.0 Mil.

Revenue was 47.973 + 25.568 + 58.686 + 44.788 = ¥177.0 Mil.
Gross Profit was 42.685 + 21.102 + 40.372 + 34.813 = ¥139.0 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(4641.815 + 4561.382 + 4497.589 + 4275.509 + 4191.356) / 5 = ¥4433.5302 Mil.
Total Assets at the begining of last year (Mar24) was ¥4,641.8 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,094.0 Mil.
Total Current Assets was ¥1,658.5 Mil.
Total Current Liabilities was ¥1,756.4 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Mabwell (Shanghai) Bioscience Co's current Net Income (TTM) was -919.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Mabwell (Shanghai) Bioscience Co's current Cash Flow from Operations (TTM) was -307.8. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-919.55/4191.356
=-0.21939201

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-1129.989/4641.815
=-0.24343689

Mabwell (Shanghai) Bioscience Co's return on assets of this year was -0.21939201. Mabwell (Shanghai) Bioscience Co's return on assets of last year was -0.24343689. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Mabwell (Shanghai) Bioscience Co's current Net Income (TTM) was -919.6. Mabwell (Shanghai) Bioscience Co's current Cash Flow from Operations (TTM) was -307.8. ==> -307.8 > -919.6 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1534.085/4462.2386
=0.34379269

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1093.999/4433.5302
=0.24675573

Mabwell (Shanghai) Bioscience Co's gearing of this year was 0.34379269. Mabwell (Shanghai) Bioscience Co's gearing of last year was 0.24675573. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=2112.717/2411.813
=0.87598707

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1658.453/1756.408
=0.94422993

Mabwell (Shanghai) Bioscience Co's current ratio of this year was 0.87598707. Mabwell (Shanghai) Bioscience Co's current ratio of last year was 0.94422993. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Mabwell (Shanghai) Bioscience Co's number of shares in issue this year was 396.629. Mabwell (Shanghai) Bioscience Co's number of shares in issue last year was 399.628. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=660.404/745.324
=0.88606297

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=138.972/177.015
=0.78508601

Mabwell (Shanghai) Bioscience Co's gross margin of this year was 0.88606297. Mabwell (Shanghai) Bioscience Co's gross margin of last year was 0.78508601. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=745.324/4191.356
=0.17782407

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=177.015/4641.815
=0.03813487

Mabwell (Shanghai) Bioscience Co's asset turnover of this year was 0.17782407. Mabwell (Shanghai) Bioscience Co's asset turnover of last year was 0.03813487. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+1+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Mabwell (Shanghai) Bioscience Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Mabwell (Shanghai) Bioscience Co (SHSE:688062) has a Piotroski F-Score of 5 as of Jul. 03, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mabwell (Shanghai) Bioscience Co and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Mabwell (Shanghai) Bioscience Co's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Mabwell (Shanghai) Bioscience Co ranks #201 out of 1336 companies in the Biotechnology industry, placing it in the top 15%.
Is Mabwell (Shanghai) Bioscience Co's Piotroski F-Score too high?
Mabwell (Shanghai) Bioscience Co's current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Mabwell (Shanghai) Bioscience Co's value of 5 is 66.7% above this industry median. Based on the distribution chart, Mabwell (Shanghai) Bioscience Co ranks #201 out of 1336 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Mabwell (Shanghai) Bioscience Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabwell (Shanghai) Bioscience Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabwell (Shanghai) Bioscience Co ranks #201 out of 1336 companies for Piotroski F-Score. This places Mabwell (Shanghai) Bioscience Co in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Mabwell (Shanghai) Bioscience Co's value of 5 is 66.7% above this benchmark. Historically, Mabwell (Shanghai) Bioscience Co's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Mabwell (Shanghai) Bioscience Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,336 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mabwell (Shanghai) Bioscience Co's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Mabwell (Shanghai) Bioscience Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mabwell (Shanghai) Bioscience Co's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabwell (Shanghai) Bioscience Co stock overvalued right now?
Based on GuruFocus' analysis, Mabwell (Shanghai) Bioscience Co (SHSE:688062) is currently considered Possible Value Trap. The stock's GF Value™ is ¥127.93, compared to a current price of ¥32.06 — trading 74.9% below its estimated fair value. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 66.7% above the Biotechnology industry median of 3.00. Mabwell (Shanghai) Bioscience Co's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Mabwell (Shanghai) Bioscience Co (SHSE:688062), the current Piotroski F-Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabwell (Shanghai) Bioscience Co (SHSE:688062) Overvalued in 2026?

Based on GuruFocus' analysis, Mabwell (Shanghai) Bioscience Co stock appears to be undervalued. The current stock price of ¥32.06 is trading 74.9% below its estimated GF Value™ of ¥127.93. GuruFocus considers Mabwell (Shanghai) Bioscience Co to be Possible Value Trap.

Key valuation signals for SHSE:688062:

  • Piotroski F-Score: 5 (25% above median its 10-year median of 4.00)
  • GF Value™: ¥127.93 vs. price of ¥32.06 (74.9% below fair value)
  • GF Score™: 61/100 with 5 warning signs
  • Industry Position: 66.7% above the Biotechnology median (#201 of 1336)

No single metric tells the full story. See the SHSE:688062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mabwell (Shanghai) Bioscience Co Business Description

Other Exchanges 02493:Hong Kong
Address No. 230, Cailun Road, Room 105, Building 2, Pilot Free Trade Zone, Shanghai, CHN, 201210
Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.
61GF Score

Get the complete analysis for SHSE:688062

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥32.06
Price
¥127.93
GF Value